OXiGENE Inc (NASDAQ:OXGN)

1.44
Delayed Data
As of Mar 30
 +0.02 / +1.41%
Today’s Change
1.34
Today|||52-Week Range
3.92
-10.56%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$29.4M

Company Description

Oxigene, Inc. engages in the development of therapeutics to treat cancer and eye diseases. It offers anti-vascular drugs referred to as vascular disrupting agents. Its products include Zybrestat (fosbretabulin) and Zybrestat Topical. The company was founded in 1988 and is headquartered in South San Francisco, CA.

Contact Information

Oxigene, Inc.
701 Gateway Boulevard
South San Francisco California 94080
P:(650) 635-7000
Investor Relations:

Employees

Shareholders

Other institutional7.07%
Mutual fund holders4.80%
Individual stakeholders0.93%

Top Executives

David ChaplinPresident, Chief Executive Officer & Director
Barbara RichingChief Financial Officer & Vice President
Jai BalkissoonVice President-Clinical Development
Kathleen M. LeeVice President-Chemistry, Manufacturing & Controls
Ronald W. PeroFounding Member

To view my watchlist

Not a member yet?

Sign up now for a free account